Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI study of deleobuvir and faldaprevir in healthy volunteers
NCT02182401Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2009
- Primary completion
- Aug 2009
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 1, open-label, single-arm trial of deleobuvir and faldaprevir in hepatitis C (HCV), sponsored by Boehringer Ingelheim. Primary endpoints: Steady-state Maximum Plasma Concentration and Steady-state Area Under the Curve. Started Jul 2009; status: terminated.
02
Drugs
deleobuvirfaldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02182401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182401.